SCHEMBL16176554

SCHEMBL16176554

CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](C=C(C)C(=O)NS(=O)(=O)Cc1cccc([N+](=O)[O-])c1)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 2/20 0.53
▸ MAOB P27338 2/20 0.34
▸ ADAMTS4 O75173 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ OPRK1 P41145 2/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ MAPT P10636 2/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ CXCR3 P49682 1/20 0.31
▸ RORC P51449 1/20 0.31
▸ PSMB1 P20618 1/20 0.31
▸ PSMB5 P28074 1/20 0.31
▸ PSMB2 P49721 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19282605 1.00 TUBB1 (0.53) TUBB1MAOBADAMTS4MMP13OPRK1
SCHEMBL16176550 1.00 TUBB1 (0.53) TUBB1MAOBADAMTS4MMP13OPRK1
SCHEMBL16176553 1.00 TUBB1 (0.53) TUBB1MAOBADAMTS4MMP13OPRK1
SCHEMBL20723974 1.00 TUBB1 (0.53) TUBB1MAOBADAMTS4MMP13OPRK1
SCHEMBL16176277 0.92 TUBB1 (0.53) TUBB1MAPTGAAMEN1KMT2A
SCHEMBL16176274 0.92 TUBB1 (0.53) TUBB1MAPTGAAMEN1KMT2A
SCHEMBL16176275 0.92 TUBB1 (0.53) TUBB1MAPTGAAMEN1KMT2A
SCHEMBL20723975 0.92 TUBB1 (0.53) TUBB1MAPTGAAMEN1KMT2A
SCHEMBL19282673 0.92 TUBB1 (0.53) TUBB1MAPTGAAMEN1KMT2A
SCHEMBL20724022 0.90 TUBB1 (0.60) TUBB1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12303544-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS BC INC. (CA) 2025-05-20 — — US disclosed
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-12-07 — — US disclosed
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS BC INC. 2023-04-04 — — US disclosed
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2019-09-05 — — US disclosed
EP-2968440-B1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS INC (CA) 2019-06-05 — — EP disclosed
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2019-02-12 — — US disclosed
US-9522876-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2016-12-20 — — US disclosed
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2016-02-11 — — US disclosed
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, BOD1L1 TUBB1 106/4885MAOB 3060/4885ADAMTS4 3349/4885
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, CCNB2, CCNB3 TUBB1 236/4885MAOB 3214/4885ADAMTS4 3296/4885
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, CCNB2 TUBB1 107/4885MAOB 3101/4885ADAMTS4 3264/4885
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 TUBB1 106/4885MAOB 3060/4885ADAMTS4 3349/4885
US-12303544-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, BOD1L1 TUBB1 106/4885MAOB 3060/4885ADAMTS4 3349/4885
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 TUBB1 106/4885MAOB 3060/4885ADAMTS4 3349/4885
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, CCNB2 TUBB1 107/4885MAOB 3101/4885ADAMTS4 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback